Topics

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

07:33 EDT 13 Sep 2019 | FDA

FDA warns about severe lung inflammation with the CDK 4/6 inhibitors Ibrance, Kisqali, and Verzenio used to treat some breast cancers. Monitor patients for hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.

Original Article: FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

NEXT ARTICLE

More From BioPortfolio on "FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...